The stock of Akebia Therapeutics Inc (NASDAQ: AKBA) has decreased by -5.13 when compared to last closing price of 2.24.Despite this, the company has seen a loss of -7.61% in its stock price over the last five trading days. prnewswire.com reported 2025-01-13 that New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass.
Is It Worth Investing in Akebia Therapeutics Inc (NASDAQ: AKBA) Right Now?
Additionally, the 36-month beta value for AKBA is 0.74. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKBA is 207.59M and currently, short sellers hold a 8.67% ratio of that float. The average trading volume of AKBA on February 03, 2025 was 2.34M shares.
AKBA’s Market Performance
AKBA stock saw an increase of -7.61% in the past week, with a monthly gain of 11.84% and a quarterly increase of 25.00%. The volatility ratio for the week is 4.71%, and the volatility levels for the last 30 days are 5.34% for Akebia Therapeutics Inc (AKBA). The simple moving average for the past 20 days is 1.25% for AKBA’s stock, with a 41.57% simple moving average for the past 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at 6.68% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.31% of loss for the given period.
Volatility was left at 5.34%, however, over the last 30 days, the volatility rate increased by 4.71%, as shares surge +13.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.72% upper at present.
During the last 5 trading sessions, AKBA fell by -6.30%, which changed the moving average for the period of 200-days by +53.93% in comparison to the 20-day moving average, which settled at $2.10. In addition, Akebia Therapeutics Inc saw 11.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Hadas Nicole R., who sale 12,016 shares at the price of $1.26 back on May 13 ’24. After this action, Hadas Nicole R. now owns 651,243 shares of Akebia Therapeutics Inc, valued at $15,140 using the latest closing price.
Dahan Michel, the SVP, Chief Operating Officer of Akebia Therapeutics Inc, sale 34,840 shares at $1.26 during a trade that took place back on May 13 ’24, which means that Dahan Michel is holding 672,092 shares at $43,898 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.63 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.27. The total capital return value is set at -0.25.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated -26.68 points at debt to capital in total, while cash flow to debt ratio is standing at -0.79. The debt to equity ratio resting at -0.96. The interest coverage ratio of the stock is -2.73.
Currently, EBITDA for the company is -8.27 million with net debt to EBITDA at 2.79. When we switch over and look at the enterprise to sales, we see a ratio of 2.83. The receivables turnover for the company is 5.28for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
In conclusion, Akebia Therapeutics Inc (AKBA) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
